Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Amortization of Deferred Charges (2021 - 2024)

Historic Amortization of Deferred Charges for Bioadaptives (BDPT) over the last 4 years, with Q2 2024 value amounting to $8387.0.

  • Bioadaptives' Amortization of Deferred Charges fell 8010.3% to $8387.0 in Q2 2024 from the same period last year, while for Dec 2024 it was $52592.0, marking a year-over-year decrease of 5601.02%. This contributed to the annual value of $52592.0 for FY2024, which is 5601.02% down from last year.
  • Bioadaptives' Amortization of Deferred Charges amounted to $8387.0 in Q2 2024, which was down 8010.3% from $44205.0 recorded in Q1 2024.
  • In the past 5 years, Bioadaptives' Amortization of Deferred Charges registered a high of $118450.0 during Q4 2021, and its lowest value of $2680.0 during Q2 2021.
  • Its 4-year average for Amortization of Deferred Charges is $44876.0, with a median of $43178.5 in 2023.
  • In the last 5 years, Bioadaptives' Amortization of Deferred Charges soared by 221735.07% in 2022 and then plummeted by 8783.82% in 2023.
  • Over the past 4 years, Bioadaptives' Amortization of Deferred Charges (Quarter) stood at $118450.0 in 2021, then tumbled by 34.18% to $77965.0 in 2022, then crashed by 65.07% to $27237.0 in 2023, then tumbled by 69.21% to $8387.0 in 2024.
  • Its Amortization of Deferred Charges stands at $8387.0 for Q2 2024, versus $44205.0 for Q1 2024 and $27237.0 for Q4 2023.